📊 KYMR Key Takeaways
Is Kymera Therapeutics, Inc. (KYMR) a Good Investment?
Kymera is a pre-commercial biotech with a strong balance sheet but severe cash burn of $88.8M annually against only $144.1M cash, yielding approximately 1.6 years of runway. Declining revenue (-16.7% YoY) despite early-stage status signals pipeline commercialization challenges. Shareholder dilution is highly likely without significant capital injection or rapid clinical progress.
Fundamentals show severe, widening operating and net losses with deeply negative free cash flow and a double‑digit revenue decline, indicating weak profitability and uncertain growth quality. The balance sheet is strong (ample cash, no debt), but the current burn rate suggests a limited runway without a step-change in operating efficiency or sizable non-dilutive funding.
Why Buy Kymera Therapeutics, Inc. Stock? KYMR Key Strengths
- Zero debt with debt/equity of 0.00x and only $129.4M liabilities against $1.7B assets
- Exceptional liquidity with current ratio of 10.81x providing operational flexibility
- Substantial stockholders' equity of $1.5B offers financial cushion for development activities
- Very strong liquidity (10.47x current ratio)
- Debt-free balance sheet with low liabilities
- Large equity base supporting R&D investment
KYMR Stock Risks: Kymera Therapeutics, Inc. Investment Risks
- Cash runway of only 1.6 years at current $88.8M annual operating burn rate
- Revenue declining 16.7% YoY is a red flag for development-stage biotech with pipeline assets
- Operating margin of -244.9% indicates pipeline commercialization is not offsetting R&D spending
- Will require dilutive equity financing or debt within 18 months
- Biotech drug development execution risk with no guarantee of clinical or commercial success
- Sustained heavy cash burn and deeply negative FCF margin
- Declining revenue and reliance on milestone/collaboration income
- Potential need for dilutive financing if losses persist
Key Metrics to Watch
- Monthly operating cash burn rate and updated cash runway estimates
- Quarterly revenue trend and clinical trial milestones for pipeline assets
- Equity financing announcements and shareholder dilution impact
- Operating cash flow burn rate
- Cash & equivalents relative to burn (runway)
Kymera Therapeutics, Inc. (KYMR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.81x current ratio provides a solid financial cushion.
KYMR Profit Margin, ROE & Profitability Analysis
KYMR vs Healthcare Sector: How Kymera Therapeutics, Inc. Compares
How Kymera Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kymera Therapeutics, Inc. Stock Overvalued? KYMR Valuation Analysis 2026
Based on fundamental analysis, Kymera Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kymera Therapeutics, Inc. Balance Sheet: KYMR Debt, Cash & Liquidity
KYMR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kymera Therapeutics, Inc.'s revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $-2.52 indicates the company is currently unprofitable.
KYMR Revenue Growth, EPS Growth & YoY Performance
KYMR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.1M | -$65.6M | $-0.71 |
| Q3 2025 | $2.8M | -$62.5M | $-0.82 |
| Q2 2025 | $11.5M | -$42.1M | $-0.58 |
| Q1 2025 | $10.3M | -$48.6M | $-0.69 |
| Q3 2024 | $3.7M | -$52.9M | $-0.82 |
| Q2 2024 | $16.5M | -$38.8M | $-0.58 |
| Q1 2024 | $9.5M | -$40.9M | $-0.69 |
| Q3 2023 | $4.7M | -$43.0M | $-0.79 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kymera Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KYMR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kymera Therapeutics, Inc. (CIK: 0001815442)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KYMR
What is the AI rating for KYMR?
Kymera Therapeutics, Inc. (KYMR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KYMR's key strengths?
Claude: Zero debt with debt/equity of 0.00x and only $129.4M liabilities against $1.7B assets. Exceptional liquidity with current ratio of 10.81x providing operational flexibility. ChatGPT: Very strong liquidity (10.47x current ratio). Debt-free balance sheet with low liabilities.
What are the risks of investing in KYMR?
Claude: Cash runway of only 1.6 years at current $88.8M annual operating burn rate. Revenue declining 16.7% YoY is a red flag for development-stage biotech with pipeline assets. ChatGPT: Sustained heavy cash burn and deeply negative FCF margin. Declining revenue and reliance on milestone/collaboration income.
What is KYMR's revenue and growth?
Kymera Therapeutics, Inc. reported revenue of $34.4M.
Does KYMR pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
Where can I find KYMR SEC filings?
Official SEC filings for Kymera Therapeutics, Inc. (CIK: 0001815442) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KYMR's EPS?
Kymera Therapeutics, Inc. has a diluted EPS of $-0.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KYMR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Kymera Therapeutics, Inc. has a SELL rating with 73% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KYMR stock overvalued or undervalued?
Valuation metrics for KYMR: ROE of -4.5% (sector avg: 15%), net margin of -201.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KYMR stock in 2026?
Our dual AI analysis gives Kymera Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KYMR's free cash flow?
Kymera Therapeutics, Inc.'s operating cash flow is $-88.8M, with capital expenditures of $434.0K. FCF margin is -259.8%.
How does KYMR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -201.5% (avg: 12%), ROE -4.5% (avg: 15%), current ratio 10.81 (avg: 2).